30-Day and 1-Year Outcomes From the Optimize PRO TAVR Evolut FX Addendum Study
JACC: Cardiovascular Interventions · 2025-08 · 18 (16) · 2004-2017
DOI: 10.1016/j.jcin.2025.06.021 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-08. Verfasst von Hemal Gada und 24 weiteren Autor:innen. Beteiligte Einrichtung: University of Pittsburgh Medical Center Central Pennsylvania Hospitals, Harrisburg, Pennsylvania, USA. Electronic address: gadah@upmc.edu. Hauptthemen laut MEDLINE: Aortic Valve, Aortic Valve Stenosis, Heart Valve Prosthesis, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medtronic Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Pittsburgh Medical Center Central Pennsylvania Hospitals, Harrisburg, Pennsylvania, USA. Electronic address: gadah@upmc.edu.
- Allegheny General Hospital, Pittsburgh, Pennsylvania, USA.
- University of Michigan-Health System University Hospital, Ann Arbor, Michigan, USA.
- Emory University, Atlanta, Georgia, USA.
- Saint Vincent's Medical Center, Bridgeport, Connecticut, USA.
- University of Pittsburgh Medical Center Presbyterian, Pittsburgh, Pennsylvania, USA.
Förderung
- Medtronic Inc
Zitieren
APA
Gada, H., Khalil, R. F., Chetcuti, S. J., Deeb, G. M., Grubb, K. J., Greenbaum, A. B., Lorenz, D., Jumper, R. D., Sultan, I., Kliner, D., Mahoney, P., Talreja, D. R., Ahmed, M. I., Rovin, J. D., Lin, L., Sorajja, P., Fraser, D. G. W., Mittal, S., Nazif, T., …, & Yakubov, S. J. (2025). 30-Day and 1-Year Outcomes From the Optimize PRO TAVR Evolut FX Addendum Study. JACC: Cardiovascular Interventions, 18(16), 2004-2017. https://doi.org/10.1016/j.jcin.2025.06.021
Vancouver
Gada H, Khalil RF, Chetcuti SJ, Deeb GM, Grubb KJ, Greenbaum AB, et al. 30-Day and 1-Year Outcomes From the Optimize PRO TAVR Evolut FX Addendum Study. JACC: Cardiovascular Interventions. 2025;18(16):2004-2017. doi:10.1016/j.jcin.2025.06.021
BibTeX
@article{Gada2025,
author = {Gada, Hemal and Khalil, Ramzi F and Chetcuti, Stanley J and Deeb, G Michael and Grubb, Kendra J and Greenbaum, Adam B and Lorenz, David and Jumper, Robert D and Sultan, Ibrahim and Kliner, Dustin and Mahoney, Paul and Talreja, Deepak R and Ahmed, Mustafa I and Rovin, Joshua D and Lin, Lang and Sorajja, Paul and Fraser, Douglas G W and Mittal, Suneet and Nazif, Tamim and Rodes-Cabau, Josep and Vora, Amit N and Ertelt, Kathleen and Tenhoff, Amanda C and Yeh, Yu Jung and Yakubov, Steven J},
title = {30-Day and 1-Year Outcomes From the Optimize PRO TAVR Evolut FX Addendum Study},
journal = {JACC: Cardiovascular Interventions},
year = {2025},
volume = {18},
number = {16},
pages = {2004--2017},
doi = {10.1016/j.jcin.2025.06.021}
}
EUVIMED